<DOC>
	<DOCNO>NCT00734565</DOCNO>
	<brief_summary>This study investigate safety reactogenicity monovalent conjugate vaccine Haemophilus influenzae type b healthy child</brief_summary>
	<brief_title>Safety Reactogenicity Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Haemophilus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Infants either sex , age 16 20 month / 2 4 month good health determine : medical history physical examination clinical judgment investigator ; available visit schedule study able comply study regulation ; write informed consent obtain , least one parent legal guardian parent legal guardian unwilling unable give write informed consent participate study ; infant present previous disease potentially related Haemophilus influenzae type b ; infant household contact and/or intimate exposure previous 30 day individual ascertain Haemophilus influenzae type b disease ; infant receive Haemophilus influenzae type b immunization dose ( 1620 month old child receive booster vaccination already ) ; premature ( 37th week gestation ) birth weight less 2500 g ; history anaphylactic shock , asthma , urticaria allergic reaction previous vaccination hypersensitivity vaccine component ; fever ≥38.0 °C ( axillary body temperature ) and/or significant acute chronic infection require systemic antibiotic antiviral therapy within past 7 day enrollment ; subject serious chronic disease cardiac , neurological , metabolic , hematologic , neoplastic disease ; known/suspected immunodeficiency , autoimmune disease , immunologic disorder ; subject neurological disorder , e.g. , epilepsy history seizure disorder ; subject clinically significant genetic anomaly ; treatment corticosteroid immunosuppressive drug ; treatment parenteral immunoglobulin preparation , blood product , and/or plasma derivative ( : within past 3 month applicable child 16 20 month ) ; vaccination administer within 2 week ( 14 day ) enrollment ; participation investigational trial simultaneously ; plan surgery study period ; condition , , opinion investigator , might interfere evaluation study objective</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>20 Months</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>vaccine</keyword>
	<keyword>prevention</keyword>
	<keyword>haemophilus influenzae type b</keyword>
	<keyword>child</keyword>
</DOC>